Loading
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Previous close
$16.03
+$0.57 · +3.69%
Regular session · ET · Market data may be delayed.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Day range
Current $16.03
52-week range
Current $16.03
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
29
Expensive
Sentiment
50
Mixed
Risk
47
Elevated Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Day range
Current $16.03
52-week range
Current $16.03
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 3.11M USD | — | 3.73M USD | 2.64M USD | 829K USD |
| Gross profit | −3.11M USD | — | −3.73M USD | −2.64M USD | −829K USD |
| Research and development | 92.85M USD | 115.36M USD | 103.82M USD | 112.46M USD | 73.92M USD |
| Selling, general, and administrative | 38.55M USD | 41.73M USD | 37.7M USD | 32.99M USD | 22.62M USD |
| Operating expenses | 128.3M USD | 179.59M USD | 137.79M USD | 244.81M USD | 124.05M USD |
| Interest income | 16.61M USD | 20.09M USD | 16.71M USD | 4.9M USD | 190K USD |
| Interest expense | — | — | — | 201.36M USD | — |
| Depreciation and amortization | 3.11M USD | 3.81M USD | 3.73M USD | 2.64M USD | 829K USD |
| Operating income | −131.41M USD | −179.59M USD | −141.53M USD | −247.45M USD | −124.88M USD |
| Net income | −124.55M USD | −161.65M USD | −125.04M USD | −242.81M USD | −122.76M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$22.50
40.36% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI175.27M0.01%2.3T USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI131.31M1.33%9.87B USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM90.15M0.12%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF56.2M0.06%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO31.48M0.23%13.92B USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB29.52M0.28%10.82B USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA23.75M0.11%21.82B USD0.03%$32.79+0.40%
Vanguard Russell 2000 ETFVTWO22.65M0.12%18B USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
